Atea/$AVIR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Atea
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
- Ticker
- $AVIR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 55
- Headquarters
- Boston, United States
- Website
- ateapharma.com
Atea Metrics
BasicAdvanced
$346M
-
-$2.10
0.29
-
Price and volume
Market cap
$346M
Beta
0.29
52-week high
$6.45
52-week low
$2.87
Average daily volume
301K
Financial strength
Current ratio
8.131
Quick ratio
7.803
Total debt to equity
0.002
Profitability
EBITDA (TTM)
-182.858
Effective tax rate (TTM)
3.78%
Management effectiveness
Return on assets (TTM)
-36.72%
Return on equity (TTM)
-58.14%
Valuation
Price to book
1.7
Price to tangible book (TTM)
1.7
Price to free cash flow (TTM)
-2.24
Free cash flow yield (TTM)
-44.64%
Free cash flow per share (TTM)
-1.928
Growth
Earnings per share change (TTM)
30.03%
3-year earnings per share growth (CAGR)
18.05%
What the Analysts think about Atea
Analyst ratings (Buy, Hold, Sell) for Atea stock.
Analyst projections of the future price of Atea stock.
Bulls say / Bears say
In the Phase 3 C-BEYOND trial, bemnifosbuvir/ruzasvir met its non-inferiority target, with a 93.9% cure rate overall; patients without cirrhosis had a 93.5% rate after eight weeks, versus 94.6% after 12 weeks with the comparator. That shorter course could make treatment easier to complete. (GlobeNewswire)
Atea has completed enrolment in its second Phase 3 HCV trial, with more than 880 patients across 17 countries. Results are expected in early 2027 and, if positive, the company is targeting an FDA application in the second quarter of 2027. (GlobeNewswire)
AT-587 has entered Phase 1 testing for hepatitis E, a disease with no approved antiviral therapy. If early safety and later efficacy studies succeed, it could give Atea a second potential product beyond its HCV programme. (GlobeNewswire)
C-BEYOND showed non-inferiority, not superior cure rates: the comparator recorded 94.8% overall versus 93.9% for Atea’s regimen. A shorter course may not be enough to persuade clinicians and payers to switch from an established treatment that already cures most patients. (GlobeNewswire)
The global Phase 3 C-FORWARD results are still pending and are needed to support the planned regulatory filing. Any disappointing result or delay could push back Atea’s HCV approval plans. (GlobeNewswire)
Cash and investments fell from $301.8 million at the end of 2025 to $219.5 million at June 2026, while the company remains pre-commercial. Atea expects its cash to last through 2027, leaving financing risk if trials or regulatory steps take longer than planned. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.
Atea Financial Performance
Revenues and expenses
Atea Earnings Performance
Company profitability
Upcoming events
No upcoming events
Atea News
AllArticlesVideos
Funds containing Atea
Fund name | Fund size | $AVIR weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.02% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.